Skip to main content

Cancer immunotherapy

In recent years, cancer immunotherapy has achieved some of the most transformational successes in improving the lives of patients with cancer. Despite this unprecedented progress, we are also experiencing new challenges in tailoring these agents to maximize clinical benefit to the right patients.

In order to select patients for appropriate single-agent and combination cancer immuno-therapeutic clinical trials, it is becoming increasingly important to develop and validate technically robust, biologically relevant, and clinically useful individual biomarkers, multiplex biomarker panels, and/or immune gene/molecular signatures utilizing NGS. With the approval of a number of immunohistochemical assays for PD-L1, microsatellite instability, and tumor mutation burden as predictors of response to immunotherapies in specific patient populations with various cancers, there is an urgent need to standardize and adopt these methodologies in the clinic, so that we can rapidly advance the field of personalized immuno-oncology-pathology in order to maximize benefits to our patients.

In practice, we need well-integrated, multi-disciplinary teamwork among pre-clinical scientists, tumor biologists, pathologists, oncologists, image analysts, statisticians, and bioinformaticians working closely with the biomarker teams in academia, industry, and diagnostic companies to fully characterize and match the tumor immune microenvironment (TIME) in a patient’s tumor with the available single-agent or combinatorial immunotherapies. This will also include determination of the status of various biologic pathways of sensitivity or resistance to immuno-therapies, the status of tumor immune cells, and the upregulation or downregulation of the various other mechanisms of tumor progression and resistance to targeted and immuno-therapies.

In order to bring together the most important basic, translational, and clinical advances in the highly complex and rapidly evolving fields of cancer immunotherapy, biomarkers, and diagnostic research and practice, Cancer Cell International has launched this thematic series, “Cancer immunotherapy,” which will comprise of reviews, original research articles, commentaries, and editorials, with the ultimate goal to provide our global audience with a highly informative collection of articles on some of the most impactful advances being made at the forefront of immuno-oncology biomarkers and diagnostics across the globe. 

To submit to Cancer Cell International please click here. See also the journal's submission guidelines.

Aejaz Nasir, MD, M.Phil, FCAP
Associate Editor, Cancer Cell International

New Content Item © © Amornrat Phuchom / Getty Images / iStock
 

  1. Increasing evidence indicates that the tumor microenvironment appears to play an increasingly important role in cancer progression and therapeutic resistance. Several types of cells within the tumor stroma had...

    Authors: Xiuyun Xuan, Chunxia Tian, Mengjie Zhao, Yanhong Sun and Changzheng Huang

    Citation: Cancer Cell International 2021 21:595

    Content type: Review

    Published on:

  2. Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to c...

    Authors: Yan Zhang, Yuanfei Shi, Huafei Shen, Lihong Shou, Qiu Fang, Xiaolong Zheng, Mingyu Zhu, Xin Huang, Jiansong Huang, Li Li, De Zhou, Lixia Zhu, Jingjing Zhu, Xiujin Ye, Jie Jin and Wanzhuo Xie

    Citation: Cancer Cell International 2021 21:573

    Content type: Primary research

    Published on:

  3. The epigenetic regulator additional sex combs-like 1 (ASXL1) is an adverse prognostic factor in acute myeloid leukemia (AML). However, the mutational spectrum and prognostic factors of ASXL1-mutated (ASXL1+) AML ...

    Authors: Yi Fan, Linxiao Liao, Yajun Liu, Zhenzhen Wu, Chong Wang, Zhongxing Jiang, Shujuan Wang and Yanfang Liu

    Citation: Cancer Cell International 2021 21:526

    Content type: Primary research

    Published on:

  4. Comprehensive analysis of omics data, such as genome, transcriptome, proteome, metabolome, and interactome, is a crucial technique for elucidating the complex mechanism of cancer onset and progression. Recentl...

    Authors: Ichidai Tanaka, Taiki Furukawa and Masahiro Morise

    Citation: Cancer Cell International 2021 21:454

    Content type: Review

    Published on:

  5. Taking advantage of nanobodies (Nbs) in immunotherapy, we investigated the cytotoxicity of Nb-based chimeric antigen receptor T cells (Nb CAR-T) against lymphoma cells.

    Authors: Hongxia Wang, Liyan Wang, Yanning Li, Guangqi Li, Xiaochun Zhang, Dan Jiang, Yanting Zhang, Liyuan Liu, Yuankui Chu and Guangxian Xu

    Citation: Cancer Cell International 2021 21:450

    Content type: Primary research

    Published on:

  6. Protopine is an isoquinoline alkaloid that possesses various biological activities including the anti-tumour activity. However, the effects of protopine on liver carcinoma cells are still elusive. The aim of t...

    Authors: Chunhui Nie, Bei Wang, Baoquan Wang, Ning Lv, Rui Yu and Enfan Zhang

    Citation: Cancer Cell International 2021 21:396

    Content type: Primary research

    Published on: